a novel approach to liquid biopsy.
We are looking where others are not.
Exai is developing liquid biopsy tests that detect a new class of cancer-associated small non-coding RNA biomarkers, termed orphan non-coding RNAs (oncRNAs). The RNA content of the transcriptome provides a more dynamic and comprehensive view of actionable cancer biology than the genome’s DNA content. oncRNA-based tests have high sensitivity and specificity because oncRNAs are abundant in the blood of patients with cancer and largely absent in people without cancer.
In studies of more than 16,000 patients, Exai has identified hundreds of thousands of unique oncRNAs, which comprise an extensive catalog that is enabling Exai to develop novel RNA-based tests for early cancer detection.